Although PLC levels may serve as a biomarker of the magnitude of myocardial ischemia and reperfusion injury, our study suggests that targeting PLC formation, specifically, does not hold a therapeutic promise in the context of myocardial infarction. This evidence concerns the gene HSPG2 and myocardial infarction.